Pharma outsourcing: people on the move
Outsourcing-Pharma.com presents its latest round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.
FDA seizes drugs worth $74,000
The US Food and Drug Administration (FDA) has ordered the seizure of $74,000 worth of Xiadafil VIP tablets after SEI Pharmaceuticals refused to withdraw them from the market.
Abbott and Pfizer shed jobs as Gilead plans growth
in-PharmaTechnologist.com’s periodic round-up of employment developments in the pharmaceutical manufacturing industry includes news on Abbott, Pfizer, Gilead and Clarcor.
FDA clears APP’s Barceloneta plant
APP Pharmaceuticals, currently the sole supplier of therapeutic heparin vials to the US market, has received FDA approval to manufacture three new formulations of the blood-thinner at its plant in Barceloneta, Puerto Rico.
NJ and the shifting landscape of pharma employment
People employed in the pharmaceutical industry in New Jersey, USA fell by one per cent in 2007, according to a report by the HealthCare Institute of New Jersey (HINJ).
Further restructuring at Cardinal?
Cardinal Health’s announcement that it is considering spinning off some of its divisions has provoked fevered speculation among industry analysts and media observers alike.
Mallinckrodt and Rubicon to develop PanExcea
CRO Rubicon Research and chemicals manufacturer Mallinckrodt Baker are teaming up to develop the PanExcea excipient range, which was launched by the latter firm’s parent company Covidien in July.
Counterfeits take chunk out of TCM sales
The impact counterfeit pharmaceuticals can have on a company’s sales has been highlighted by Tongjitang Chinese Medicines’ (TCM) second quarter results.
USP opens its first site in Brazil
The US Pharmacopeia (USP) has continued to expand its global reach by opening a site in São Paulo, Brazil; its first in Latin America.
Vaccine sales help Crucell cut Q2 loss
An increase in the sale of vaccines such as Quinvaxem and Epaxal, helped Dutch drugmaker Crucell reduce its loss some 56 per cent to €7.9m ($12.5m) in the second quarter.
HGS enlists Eden for client indentification
UK-based Eden Biodesign has been selected as marketing services partner for US drug developer Human Genome Sciences (HGS).
Manufacturing facility news in brief
in-PharmaTechnologist.com's round-up of developments in pharmaceutical manufacturing features news of SAFC’s new highly potent API plant, ISPE’s Facility of the Year Awards and Israel’s proposed entry into PIC/S.
AgenoLab first to install Roche’s new assay platform
German biotech and life science laboratory services firm AgenoLab has installed the first xCelligence real-time cell analysis system to bolster its assay offering to customers.
Sanofi and NovaMed expand distribution deal
Sanofi Aventis has extended its deal with China’s NovaMed, adding the anti-convulsant Depakine (valproic acid) to the latter firm’s distribution roster.
Genentech rejects Roche but leaves door ajar
Genentech’s special advisory committee has rejected Roche’s $44bn offer for the biotech believing that it “substantially undervalues” the company.